Nasal Delivery Devices
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/EP2013/053746, filed Feb 25, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,502,497 | Nasal Delivery Devices In force · Medium confidence | OptiNose, Inc. | In force | Medium confidence | ||
| US 11,033,696 | Nasal delivery devices In force · High confidence | OptiNose Inc. | In force | High confidence | ||
| US 10,300,229 | Nasal Delivery Devices In force · High confidence | OptiNose Inc. | In force | High confidence | ||
| Application 17/316,779 | Nasal Delivery Devices Abandoned Abandoned Aug 12, 2024 | OptiNose Inc. | Abandoned | Abandoned Aug 12, 2024 | ||
| Application 19/394,580 | Nasal Delivery Devices Pending Not granted | OptiNose Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Optinose Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.